bHLH Transcription Factors Inhibitors for Cancer Therapy: General Features for In Silico Drug Design

ISSN: 1875-533X (Online)
ISSN: 0929-8673 (Print)


Volume 21, 38 Issues, 2014


Download PDF Flyer




Current Medicinal Chemistry

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 9th of 58 in Chemistry & Medicinal
  • 49th of 254 in Pharmacology & Pharmacy
  • 96th of 291 in Biochemistry & Molecular Biology

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge
Cambridge
UK
Email: cmc@benthamscience.org

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.715
5 - Year: 4.239

bHLH Transcription Factors Inhibitors for Cancer Therapy: General Features for In Silico Drug Design

Author(s): I.F. Tsigelny, V.L. Kouznetsova, S.C. Pingle and S. Kesari

Affiliation: UCSD San Diego Supercomputer Center, 9500 Gilman Drive, La Jolla, CA 92093-0505, USA.

Abstract

Numerous basic-helix-loop-helix (bHLH) transcription factors (TF) have been found to play important roles in tumor growth and progression. Elucidation of the common features of these TFs can pave the road to possible therapeutic intervention. The existing studies of possible inhibition of these TFs are concentrated on the development of peptides or small molecules that inhibit their dimerization or prevent their DNA binding. The bHLH TFs have striking similarity in many functionally important regions, such as the helical regions of TFs that interact with each other during dimerization and have complementary sets of residues on both sides of a dimer. These are hydrophobic residues along with anionic and cationic residues with complementary charges. Such complementarity also exists in other contact regions of the bHLH TFs. They also have a very specific set of positively charged residues on the surface, which would contact DNA. Such specificity defines a common concept for an in silico design of bHLH TFs inhibitors for a number of existing and important cancer-related TFs.

Keywords: bHLH, cancer, computational drug design, drug-DNA interactions, drug–protein interactions, inhibitors, in silico, protein dimerization, transcription factor.

Purchase Online Rights and Permissions

  
  



Article Details

Volume: 21
Issue Number: 28
First Page: 3227
Last Page: 3243
Page Count: 17
DOI: 10.2174/0929867321666140414111333
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science